I'd agree. Shareholders generally trust the management where they invest. No matter how good the tech is you won't get the 'tech' (in this case a vaccine) to market without navigating the extremely complex RAs. To do this you need a good management team. I'm here because I believe we have both the tech and the management to get us across the line. I would think most long shareholders have this same belief.
Dubious distinction as DCVax-L is not a stock or price. And getting it approved and eventually successfully launched at this stage of a company’s life is what matters most. On those counts, I’d disagree with you on most things you’d say.